33 results about "Diabrezide" patented technology

The application discloses application of Xintong preparation in preparation of a medicine for treating diabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The Xintong preparation is prepared from 13 raw medicinal materials of Huangqi, Gegen, Danshen, Dangshen, Maidong, Heshouwu, Yinyanghuo, Dangui, Zaokesheng, Haizao, Kelp, Muli and Zhishi, has the effects of benefiting qi and activating blood, reducing phlegm and dredging collaterals. Pharmacodynamic experiments show that the Xintong preparation has the effect of reducing blood sugar, can effectively improve the physical conditions of polydipsia, polyphagia, polyuria and emaciation and lack of strength of an animal model of diabetes, significantly reduces the fasting blood sugar and serum insulin level, improves the oral glucose tolerance, has a definite treatment effect on type II diabetes, and expands the clinical application range of the Xintong preparation, and has a wide market application prospect.

The invention relates to the technical field of medicines, in particular to a preparation method of an anti-diabetic traditional Chinese medicine composition. Through long-term research, the raw medicinal materials are processed by adopting different processing methods, and the anti-diabetic traditional Chinese medicine composition disclosed by the invention has a good anti-diabetic effect through the steps of decocting, concentrating and the like in combination with a specific ratio. Specifically, in the aspect of processing, corresponding processing methods are adopted according to the characteristics of different medicinal materials, so that the medicine effect of the medicinal materials in the aspect of resisting diabetes mellitus is exerted to the greatest extent; in the aspect of the formula, the anti-diabetes traditional Chinese medicine composition is endowed with the function of improving diabetes mellitus through the synergistic effect of the raw materials under the specific dosage, and a new thought is provided for research and development of diabetes mellitus medicines. The result of the embodiment shows that the anti-diabetic traditional Chinese medicine composition provided by the invention has a remarkable treatment effect on diabetes, the average fasting blood-glucose is reduced by more than 23% after the composition is taken for 60 days, and the anti-diabetic traditional Chinese medicine composition is small in side effect, short in treatment cycle and remarkable in social benefit.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

The application belongs to the technical field of diabetes drugs, and particularly relates to a traditional Chinese medicine composition for treating insulin resistance of diabetes and a preparation method thereof. Main components of the composition are as follows in terms of weight parts: 20-40 parts of Huangqi, 15-25 parts of Gegen, 12-18 parts of fried Baizhu, 20-40 parts of Sangzhi, 9-15 parts of Danshen, 15-25 parts of Tianhuafen, 20-40 parts of Shanyao, 12-18 parts of Baichandou, 9-15 parts of Sharen, 9-15 parts of Qianshi and 9-15 parts of Cansha. The traditional Chinese medicine composition is prepared by matching spleen-invigorating and qi-tonifying drugs with heat-clearing and dampness-removing drugs, and by matching yin tonifying with yang raising, so that yin and yang of the spleen are generated, dampness and heat evil are removed, and the functions of invigorating the spleen, clearing heat and removing dampness are achieved. The traditional Chinese medicine composition has remarkable curative effects on improving symptoms and signs of insulin resistance of diabetes and improving the life quality of patients.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention discloses an application of miR-100 sponge in preparation of a medicine for treating type 2 diabetes mellitus. The miR-100 sponge can inhibit miR-100 in a targeted manner and close the expression of miR-100 in beta cells. The nucleic acid construct is further prepared from the nucleic acid construct, AAV8-mmu-miR-100 Sponge (AAV-Sponge) is injected into pancreatic ducts of obese diabetes mellitus mice, after treatment is conducted for 4 weeks, it is found that the sugar tolerance of the mice in a treatment group is improved, the GSIS function of beta cells is improved, and the nucleic acid construct is expected to be further applied to preparation of the medicine for treating the type 2 diabetes mellitus. The problems that current treatment methods for type 2 diabetes mellitus are deficient and the treatment cost is high are solved.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

This invention belongs to the field of pharmaceutical technology and discloses a spirocyclic triterpenoid compound, its preparation method, and its application in the preparation of antidiabetic drugs. This invention uses the whole herb of *Euphorbia humifusa* as the isolation target and employs an efficient and systematic separation and preparation method to enrich terpenoid compounds. A spirocyclic triterpenoid compound was obtained through silica gel, ODS column chromatography, and HPLC. In vitro inhibition of α-glucosidase experiments confirmed that compound I has significant hypoglycemic activity and can be used as an active ingredient in antidiabetic drugs, with broad applications.

The application provides a crystallization process and product of recombinant insulin, and relates to the technical field of biological medicine; the crystallization process comprises the following steps: mixing and dissolving recombinant insulin, an organic acid, an organic solvent, a salt and water, adding a zinc substance to obtain a crystallization solution; adjusting pH, and then standing after low-temperature stirring; and separating the recombinant insulin crystal; in the crystallization solution, when the insulin concentration is 5g / L, the organic solvent concentration is 10%-30%, and pH=8.0-9.3; when 5<insulin concentration≤10g / L, the organic solvent concentration is 15%-30%, and pH=8.8-9.5. In the absence of phenolic substances, the application realizes the successful crystallization of high-concentration recombinant insulin by adopting specific concentrations of recombinant insulin and organic solvent and adjusting pH; the crystal form is similar to that in the presence of phenol; and the obtained crystalline recombinant insulin is applied to the preparation of a drug for treating diabetes.

The invention provides a crystallization process of recombinant insulin glargine and a product, and relates to the technical field of biological medicines. The crystallization process comprises the following steps: mixing and dissolving recombinant insulin glargine, organic acid, an organic solvent, salt and water, and adding zinc substances to obtain a crystallization solution; adjusting the pH value, stirring at low temperature, standing, and separating the recombinant insulin glargine crystal; in the crystallization solution, when the concentration of insulin is 5g / L, the concentration of the organic solvent is 10-30%, and the pH is 8.0-9.3; when the concentration of insulin is more than 5 and less than or equal to 10g / L, the concentration of the organic solvent is 15-30%, and the pH is 8.8-9.5. Under the condition of no phenolic substances, the successful crystallization of the high-concentration recombinant insulin glargine is realized by adopting the specific concentration of the recombinant insulin glargine and the concentration of the organic solvent and combining the conditions of pH regulation and the like; the crystal form of the recombinant insulin glargine is similar to that of the insulin glargine with phenol, and the obtained crystallized recombinant insulin glargine is applied to preparation of drugs for treating diabetes.

The invention discloses an application of schizophyllumcommuneh in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of pharmacy. The active ingredient of the medicine for treating the type II diabetes is a schizophyllumcommuneh extract, and the preparation method of the schizophyllumcommuneh extract comprises the following steps: taking schizophyllumcommuneh as a raw material, extracting through an enzymolysis and microwave-assisted method, and then performing ethanol precipitation and spray drying to obtain the schizophyllumcommuneh extract. Based on a diabetic mouse model, in the aspect of monitoring the blood sugar content of a mouse, the Schizophyllumcommuneh is found to have prevention and treatment effects on the type 2 diabetes mellitus, and the Schizophyllumcommuneh is proved to have an exact curative effect on the type 2 diabetes mellitus. The Schizophyllumcommuneh extract prepared by the invention has the characteristics of safety and high efficiency, has potential development value for type 2 diabetes mellitus drugs, is a natural preparation, and is worthy of popularization.

The invention discloses an application of a Yindan Xinnaotong soft capsule in preparation of a medicine for treating type 2 diabetes mellitus, a luciferase reporter gene plasmid is constructed by targeted targeting of a glucagon-like peptide-1 receptor (GLP-1R), which is one of the most effective targets for treating the type 2 diabetes mellitus at the present stage, HEK-293T is used as a tool cell in vitro, and the application of the Yindan Xinnaotong soft capsule in preparation of the medicine for treating the type 2 diabetes mellitus is realized. GLP-1R luciferase reporter gene plasmids are transfected into the GLP-1R promoter, and luciferase reporter gene experiments find that the Yindan Xinnaotong soft capsule can significantly up-regulate the activity of the GLP-1R promoter. Furthermore, verification is carried out through in-vitro and in-vivo experiments, and results show that the Yindan Xinnaotong soft capsule has a certain protection effect on MIN6 cells damaged by palmitic acid and has a remarkable improvement effect on glucolipid metabolism of mice with type 2 diabetes by influencing a GLP-1R signal channel, so that the Yindan Xinnaotong soft capsule can be used as a preparation for treating the type 2 diabetes and has a good application prospect. The traditional Chinese medicine composition can be prepared into oral liquid, injection, tablets, capsules, granules, dripping pills and the like which are permissible in pharmacy.

The application discloses a crystal form of indolepropionic acid-metformin salt and a preparation method and application thereof, and belongs to the technical field of chemical medicines and crystal form processes. The X-ray powder diffraction pattern of the crystal form has characteristic diffraction peaks at 8.8°±0.2°, 12.7°±0.2°, 14.1°±0.2°, 17.2°±0.2°, 18.0°±0.2°, 18.5°±0.2° and 19.6°±0.2°. The crystal form of indolepropionic acid-metformin salt provided by the application has good stability, improved solubility and dissolution rate compared with indolepropionic acid, can solve the problem of low solubility of indolepropionic acid, and combines metformin and indolepropionic acid which have a blood sugar lowering effect, and is expected to promote the design of indolepropionic acid preparations and the application in the clinical aspect, can have a pharmacological synergistic effect in the treatment of diabetes, and has the potential to develop a drug for treating diabetes.

The invention belongs to the technical field of medicine, and provides a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preventing and treating diabetes mellitus, the traditional Chinese medicine composition comprises concha arcae, radix scrophulariae, rhizoma anemarrhenae, ginseng, radix astragali, prepared rehmannia root, dogwood, Chinese yam, moutan bark, poria cocos, radix puerariae, rhizoma atractylodis, radix salviae miltiorrhizae, earthworm, stiff silkworm and rhizoma alismatis. The invention provides a novel pharmaceutical composition for preventing and treating diabetes, which is reasonable in formula and exact in curative effect. The traditional Chinese medicine composition not only can effectively reduce blood sugar and improve core symptoms of diabetes mellitus, but also can treat diabetic complications in a targeted manner, especially can achieve synergistic prevention and treatment of diabetic feet, and solves the limitation that most of existing medicines only aim at a single symptom.

The invention discloses application of banana peel melanin to preparation of a medicine for treating diabetes mellitus, and belongs to the technical field of medicines. The melanin is separated from the banana peel through the technologies of ethanol extraction, AB-8 macroporous adsorption resin purification, infrared spectrum identification and the like, the melanin has remarkable inhibitory activity on alpha-glucosidase, the median inhibitory concentration (IC50) is as low as 3.04 mu g / mL, the inhibitory effect is superior to that of a positive control drug acarbose (IC50 is 11.10 mu g / mL), and the melanin has a good application prospect. And a high-quality natural raw material is provided for developing a novel medicine for treating diabetes. In addition, enzyme kinetic research shows that the banana peel melanin inhibits the activity of alpha-glucosidase through an anti-competitive inhibition mechanism, can effectively delay decomposition and absorption of starch substances in intestinal tracts and reduce the postprandial blood sugar peak value, and can be used for preparing safe and efficient blood sugar reducing drugs; meanwhile, high-value utilization of the banana peel waste is achieved, and the method has important economic value and environmental protection significance.

The invention belongs to the technical field of biological medicine, and particularly relates to application of BRP polypeptide in preparation of a medicine for treating diabetes. The invention discloses application of BRP polypeptide in preparation of a medicine for treating diabetes. The amino acid sequence of the BRP polypeptide is shown as SEQ ID NO. 1. Pancreas islet and cell experiments prove that the BRP polypeptide stimulates secretion of insulin, glucagon and GLP-1 in a dose-dependent manner and is independent of an ATP-dependent potassium channel. In obese diabetic mice induced by high fat diet, the BRP polypeptide is proved to be capable of remarkably promoting secretion of insulin and GLP-1 of the mice, the BRP polypeptide has a brand-new and direct hormone stimulation application potential in the aspect of medicines for treating metabolic diseases such as diabetes and obesity, and the BRP polypeptide is different from the prior art focusing on appetite inhibition and has a wide application prospect. Therefore, a research direction is provided for developing medicines for treating metabolic diseases such as diabetes mellitus and obesity.

The invention belongs to the technical field of medicine research, and particularly relates to application of nutgall or nutgall extract in preparation of antidiabetic medicine. Tests prove that the nutgall extract can remarkably reduce the blood glucose level of a diabetic animal model, and it is prompted that the nutgall extract can be used as a potential anti-diabetic medicine.

The present invention relates to the use of a pharmaceutical carrier in the preparation of an antidiabetic pharmaceutical composition. In particular, the present invention relates to the use of a pharmaceutical carrier in the preparation of an antidiabetic pharmaceutical composition, wherein the pharmaceutical carrier consists of well-mixed sesame oil and beeswax, and the antidiabetic pharmaceutical composition consists of oryzanol and berberine hydrochloride as active ingredients, wherein oryzanol is present in an amount of 1-5% by weight, berberine hydrochloride is present in an amount of 5-50% by weight, beeswax is present in an amount of 1-20% by weight, and sesame oil is present in an amount of 40-85% by weight, based on the total weight of the pharmaceutical composition.The present invention further relates to an antidiabetic pharmaceutical composition as above, which is subjected to compression, washing, drying and screening, and filling into a vial to obtain a soft capsule dosage form product. The product has advantages such as stable control of blood glucose, lowering of blood glucose level and blood lipids, protection of liver function, and reduction of gastrointestinal irritation.

The present invention provides methods for treating or preventing type 2 diabetes mellitus in patients with low HOMA2-B using tilpotide as a first-line diabetes mellitus drug treatment. The present invention provides methods of treating a patient suffering from long-term type 2 diabetes mellitus and reducing or eliminating basal insulin treatment with tilpotide, wherein such treatment lasts for at least 26 weeks.

The present invention provides a method for treating or preventing type 2 diabetes in patients with low HOMA2-B using tilzepatide as a first-line pharmaceutical treatment for diabetes. A method is also provided for treating patients with long-term type 2 diabetes using tilzepatide and reduction or elimination of basal insulin therapy, such treatment being continued for at least 26 weeks.

The invention discloses a screening method of anti-type 2 diabetes mellitus multi-target drugs based on a Boolean network, and belongs to the technical field of biological medicines. According to the method, a dynamic network model is constructed, a related signal path is converted into a calculation framework, a cooperative target combination (DPP-4 and GPR40) is identified through disturbance analysis, a minimum intervention node set is accurately positioned by utilizing attractor characteristics, a virtual screening model is constructed to screen candidate compounds, and a closed-loop process is formed. The synchronous stabilizer attractor calculation is combined with the minimum intervention node set standard, so that the analysis is more accurate, and the target combination is limited to ensure the synergistic effect. The system realizes automatic and efficient screening through integration of four functional modules. In application, the candidate compound is used for preparing the anti-type 2 diabetes medicine, and the existing treatment problem is solved. The multi-target pharmaceutical composition avoids multi-drug combination and reduces the risk. The drug combination product integrates a DPP-4 inhibitor and a GPR40 agonist, solves the problem of multi-drug combination, and provides a new treatment choice.

Systems and methods are described for determining a reference blood glucose (RefBG) metric and for determining a medicament dose or dose adjustment for a subject based at least in part the reference blood glucose metric. The RefBG metric is based on continuous and / or intermittent glucose monitoring samples and can be derived from a specified time window of the samples. One or more additional metrics of a therapeutic performance of the subject may be modeled and used to establish a target value for the RefBG metric, which may be compared to historical RefBG values to determine dose values to be avoided in future updates of medicament doses.

This invention relates to the application of anthraquinone I in the preparation of drugs for the prevention and treatment of type 2 diabetes. The method involves pulverizing the whole herb of *Patrinia scabiosifolia*, extracting it by reflux with ethanol, and concentrating under reduced pressure to obtain an extract. The extract is then sequentially extracted with equal volumes of petroleum ether, dichloromethane, and n-butanol. The dichloromethane layer is separated by silica gel column chromatography to obtain 10 fractions (Fr.1 to Fr.10). Fr.5 is further separated by ODS column chromatography, eluting with a methanol-water gradient to obtain 5 fractions (Fr.5-1 to Fr.5-5). Fr.5-4 is separated by Sephadex LH-20 column chromatography, and then purified by semi-preparative high-performance liquid chromatography to obtain anthraquinone I. The extraction method of anthraquinone I in this invention is simple and suitable for large-scale production. Anthraquinone I can inhibit α-glucosidase and can be used in the preparation of hypoglycemic drugs.

The application discloses a flavonoid carbon glycoside compound, a directional separation and preparation method and application thereof. The flavonoid carbon glycoside compound is first extracted and discovered, and is used for preparing a medicine for treating or improving diabetes. The preparation process comprises the following steps: extraction, microporous resin medium pressure chromatography rough separation, reverse phase medium pressure chromatography enrichment, reverse phase preparation column preparation, Fr411 reverse phase preparation liquid chromatography purification, and Fr412 hydrophilic preparation liquid chromatography purification. The flavonoid carbon glycoside compound separated by the application can effectively inhibit alpha-glucosidase activity, has low cost, and has a product purity greater than 95%. The technical means adopted by the application can be used for large-scale production, and is easy to scale. The reverse phase preparation liquid chromatography or the hydrophilic preparation liquid chromatography used in the separation and purification is a rapid isocratic method.

The application discloses application of a dendrobium extract in preparation of a medicine for treating type 2 diabetes, and mainly relates to the technical field of dendrobium. Specifically, the application provides a medicine for treating type 2 diabetes and containing the dendrobium extract, improves stability of components in the medicine for treating type 2 diabetes in an acid, neutral or alkaline environment, and slows down blood sugar increase. Compared with the prior art, the medicine for treating type 2 diabetes prepared by the application takes the dendrobium extract as a core, is matched with a synergistic emulsion, a rhizoma polygonati extract, a fructus corni extract, a salvia miltiorrhiza extract, a momordica charantia extract, vitamin B and trace elements of chromium, and through cooperation with traditional Chinese medicine components, can synergistically regulate blood sugar metabolism, enhance insulin sensitivity and improve microcirculation, can stabilize blood sugar, improve insulin resistance and lipid metabolism, improve immunity and cardiovascular function, and provides a safe and effective medicine for prevention and treatment of type 2 diabetes.

The invention discloses folic acid, a composition containing the folic acid and application of the folic acid. It is found and verified that folic acid can be used for increasing the number of NKG2A positive DNT cells and treating type 1 diabetes for the first time, a new direction is provided for treatment of type 1 diabetes, and the folic acid has good clinical transformation prospects. According to the invention, the folic acid and the anti-CD3 monoclonal antibody are used for preparing a composition, and the folic acid and the anti-CD3 monoclonal antibody can form a complementary synergistic effect in the aspects of enhancing immune tolerance and inhibiting autoimmunity in treatment; the combined application of the folic acid and the anti-CD3 monoclonal antibody can more effectively prevent the occurrence and development of the type 1 diabetes, reverse the hyperglycemia of the type 1 diabetes and reduce the severity of islet inflammation of NOD mice without influencing the weight of the mice, and provides a new research direction for preparing more efficient and safer type 1 diabetes medicines.

The invention provides an efficient screening method of immobilized alpha-amylase and a corn stigma source alpha-amylase inhibitor based on a magnetic carrier, and mainly solves the technical problems that the existing diabetes drugs have obvious side effects and the screening efficiency of natural active ingredients is low. In order to solve the problem of drug tolerance generally existing in treatment of type 2 diabetes mellitus, a magnetic MOF carrier is used in the scheme, and efficient immobilization of alpha-amylase is realized through a synergistic strategy of amino functional surface modification and glutaraldehyde crosslinking. The immobilized enzyme system and ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF / MS) form a combined platform, and a three-stage analysis process of magnetic enzyme reaction-precise molecular weight screening-MS / MS structure confirmation is established. Compared with the traditional tedious screening period, the technology can complete the discovery and confirmation of the active components in a short time, and provides an efficient and industrialized solution for the discovery of the plant-derived hypoglycemic lead compound.

The present invention pertains to the field of medical technology, specifically disclosing the pharmaceutical application of dimyricetin-based diselenide in type II diabetes. After four weeks of continuous administration, compared with the model control group, the test substances DMS-ASD and AQ-C-a demonstrated effects that were basically equivalent to the positive control drug, semaglutide injection, in reducing fasting blood glucose levels after 16 hours of fasting in db / db mice, reducing random blood glucose levels in db / db mice, inhibiting postprandial blood glucose elevations in db / db mice, decreasing the HbA1c content of glycated hemoglobin in db / db mice, and influencing body weight and food intake in db / db mice. The pharmaceutical application of dimyricetin-based diselenide in type II diabetes holds great promise.